Prices delayed by at least 15 minutes | Print
Valirx PLC (VAL)
ORD 0.1POpen
0.13p
Previous close
0.13p
Trade high
0.135p
Volume
1,475,119
Year high
0.55p
Year low
0.12p
Dividend yield
–
Market capitalisation
£1.72 mn
P/E ratio
–
ISIN
GB00BLH13C52
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
ValiRx PLC is a UK-based biopharmaceutical and life sciences company focused on advancing cutting-edge therapies in healthcare. The Company mainly engages in developing technologies and products in oncology therapeutics and diagnostics, with a focus on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It develops therapeutics across fields in oncology and has a portfolio of products in the pipeline, including GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in different stages of development.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 16/10/2026 | 04:26:34 | 0.135 | 2,259 | 3.05 |
| 16/10/2026 | 03:27:25 | 0.1213 | 500,000 | 606.50 |
| 16/10/2026 | 12:02:42 | 0.12 | 33,336 | 40.00 |
| 16/10/2026 | 10:47:30 | 0.1225 | 30,000 | 36.75 |
| 16/10/2026 | 10:11:07 | 0.1265 | 909,524 | 1,150.55 |